{
  "docId": "019de516-48a5-7631-970d-a6192a59c040",
  "docSlug": "5b4cac48a3342d745accb48141e027b4",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 39 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 39,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 36,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de516-48a5-7631-970d-a6192a59c040/11",
  "deckHref": "/decks/019de516-48a5-7631-970d-a6192a59c040",
  "deckJsonHref": "/decks/019de516-48a5-7631-970d-a6192a59c040.json",
  "deckAnchorHref": "/decks/019de516-48a5-7631-970d-a6192a59c040#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.026,
        "w": 0.099,
        "x": 0.043,
        "y": 0.94
      },
      "kind": "image",
      "text": "BAUSCH+LOMB",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb9eae64-78fd-4f49-9c33-29a100ac9431",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.759,
        "x": 0.154,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.\n3. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results\nof the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net\nimpact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n4. 2022 results were not fully burdened by all stand-up costs associated with the separation",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec005013-40da-4bf7-a17d-6ba48383beb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.702,
        "w": 0.91,
        "x": 0.043,
        "y": 0.157
      },
      "kind": "table",
      "text": "Bausch + Lomb 2Q23 2Q224 Reported Change Constant Currency Change2 Vision Care Revenue3 $646M $588M 10% 12% Surgical Revenue $195M $184M 6% 7% Pharmaceuticals Revenue3 $194M $169M 15% 16% Total Revenue $1,035M $941M 10% 12% Gross Profit $562M $498M 13% 15% Gross Margin 54.3% 52.9% 140 bps R&D $85M $75M (13%) (13%) R&D % of Revenue 8.2% 8.0% SG&A $417M $368M (13%) (14%) SG&A % of Revenue 40.3% 39.1% Operating Income $43M $56M Net (Loss) Income Attributable to Bausch + Lomb ($32M) $5M Net (Loss) Income Margin (3.1%) 0.5% EPS Attributable to Bausch + Lomb ($0.09) $0.01",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a1afb8d-1494-4ec5-9ada-dfdc78162ce1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.47,
        "x": 0.045,
        "y": 0.07
      },
      "kind": "title",
      "text": "2Q23 Total Bausch + Lomb P&L¹ (GAAP)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b8cf043-aef6-415a-8e08-ecf7884f2798",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "e1b30a01-0c11-4345-ab8f-ef2c1de997c1",
      "evidence": "Bausch + Lomb 2Q23 2Q224 Reported Change Constant Currency Change2 Vision Care Revenue3 $646M $588M 10% 12% Surgical Revenue $195M $184M 6% 7% Pharmaceuticals Revenue3 $194M $169M 15% 16% Total Revenue $1,035",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "9630bb99-f6be-4279-92e2-bb79342bf55e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Bausch + Lomb showcases its financial performance and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}